Sign up
Pharma Capital

Pharmaxis expects an FDA decision on Bronchitol mid-year after positive committee recommendation

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the positive recommendation received from a US Food and Drug Administration advisory committee for the use of its inhaled powder Bronchitol in adult patients with cystic fibrosis. 
 
Phillips says the US is the last major territory where Bronchitol has not yet been approved and the company expects an FDA decision mid-year.
 
Clinical trials have shown Bronchitol improves lung function in CF patients.
 
It is delivered by a portable inhaler, allowing patients to fit in taking medication with their daily lives.

 

 

View full PXS profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.